Case Details
- Citation: [2020] SGCA 7
- Title: Liberty Sky Investments Limited v Dr Goh Seng Heng
- Court: Court of Appeal of the Republic of Singapore
- Date of Decision: 10 February 2020
- Judgment Date (Reserved): 22 January 2020
- Judges: Andrew Phang Boon Leong JA, Judith Prakash JA and Belinda Ang Saw Ean J
- Procedural History / Appeals: Civil Appeals Nos 55, 56 and 57 of 2019 and Civil Appeal Summons No 100 of 2019
- Related Suits: Suit No 1311 of 2015; Suit No 457 of 2017
- Parties: Liberty Sky Investments Limited (“LSI”) and Dr Goh Seng Heng (“Goh”); Aesthetic Medical Partners Pte Ltd (“AMP”) also involved in Suit 457
- Appellant / Applicant (CA 55): Liberty Sky Investments Limited
- Respondent (CA 55): Dr Goh Seng Heng
- Appellant / Applicant (CA 56): Liberty Sky Investments Limited
- Respondent (CA 56): Dr Goh Seng Heng
- Appellant (CA 57): Dr Goh Seng Heng
- Respondent (CA 57): Liberty Sky Investments Limited
- Legal Areas: Contract; Misrepresentation (fraudulent misrepresentation); Equity (rescission and bars to rescission); Civil Procedure (pleadings; leave to adduce further evidence)
- Statutes Referenced: Evidence Act
- Cases Cited: [2020] SGCA 7 (as reported); Panatron Pte Ltd v Lee Cheow Lee [2001] 2 SLR(R) 435
- Judgment Length: 23 pages, 6,607 words
Summary
In Liberty Sky Investments Limited v Dr Goh Seng Heng, the Court of Appeal dismissed three related appeals arising from two sets of proceedings between an investment vehicle (LSI) and a medical doctor (Goh) who had induced LSI to enter into a share purchase agreement. The court upheld the trial judge’s findings that Goh made fraudulent misrepresentations concerning (i) the imminence of a trade sale of AMP shares and (ii) the likelihood of an initial public offering (IPO) within a targeted timeframe. The Court of Appeal affirmed liability for fraudulent misrepresentation and rejected arguments that LSI was not induced by the relevant statements.
On remedies, the Court of Appeal also upheld the trial judge’s approach to rescission and damages. LSI attempted to broaden its case on appeal by reframing its entitlement to rescission and full recovery as a trustee-like representative claim, and later by advancing a “new argument” that it could rescind in its personal capacity because it remained in possession of the shares. The court rejected these attempts as procedurally impermissible and substantively unmeritorious, and it refused leave to adduce further evidence in the form of investors’ affidavits. Overall, the decision underscores the strictness of pleading and appellate procedure in Singapore and the evidential and substantive requirements for rescission in cases of fraudulent misrepresentation.
What Were the Facts of This Case?
Dr Goh Seng Heng was a medical doctor who founded Aesthetic Medical Partners Pte Ltd (“AMP”) in 2008. Liberty Sky Investments Limited (“LSI”) was an investment vehicle incorporated in the Seychelles. LSI’s sole director and shareholder was Gong Ruilin (“Gong”), and Gong’s husband, Lin Lijun (“Lin”), acted as LSI’s representative in the transaction and related dealings.
On 25 November 2014, LSI executed a sale and purchase agreement (“SPA”) with Goh to purchase 32,049 shares in AMP for a purchase price of $14,422,050. The transaction was structured to be concluded quickly, and Gong and Lin did not have time to conduct due diligence on AMP. Because of the speed and the perceived risk, Gong and Lin requested protection in the form of a guarantee of their investment capital and an internal rate of return (“IRR”) of 15% per annum (the “Guarantee”). Goh informed them that AMP would provide the Guarantee.
The fraudulent misrepresentations alleged by LSI were said to have been made during a dinner on 23 October 2014 and at a meeting on 24 October 2014 (the “24 October 2014 Meeting”). The representations were twofold. First, Goh allegedly represented that there would be a trade sale of all AMP shares to a prominent person in Singapore—Peter Lim, a billionaire who owned a medical group or hospital chain. The trade sale was said to have a 99% chance of being concluded, to be likely, imminent, and expected to take place within one month or very soon (the “Trade Sale Representations”). Second, if the trade sale did not materialise, Goh allegedly represented that he intended to list AMP through an IPO on the Singapore Exchange targeted for completion around March to June 2015 (the “IPO Representations”).
After the SPA was executed, LSI sold 30,549 AMP shares to two Chinese investors (“the Chinese Investors”) at the same price that LSI paid Goh. As a result, LSI retained beneficial interest in only 1,500 AMP shares. Neither the trade sale nor the IPO occurred. Gong and Lin then brought claims against Goh and AMP. In Suit No 1311 of 2015 (“Suit 1311”), they sued for fraudulent misrepresentations. In Suit No 457 of 2017 (“Suit 457”), they sued Goh and AMP for the purchase price plus 15% IRR under the Guarantee.
What Were the Key Legal Issues?
The first key issue was whether the Court of Appeal should uphold the trial judge’s findings that the Trade Sale and IPO Representations were false and were made fraudulently. Goh challenged the factual basis for those findings, including by arguing that he only mentioned Peter Lim after the SPA was executed and that the later documentary references did not support the conclusion that he had identified the prospective buyer at the 24 October 2014 Meeting.
The second issue concerned causation and inducement: even if the representations were false, the court had to determine whether they played a real and substantial part in inducing LSI to enter into the SPA. Goh argued that the Guarantee, rather than the representations, was the real reason for entering the contract.
The third issue related to remedies for fraudulent misrepresentation, particularly rescission and the availability of equitable relief. LSI sought to expand its remedial position on appeal, including by advancing arguments that it could rescind and recover damages in respect of all 32,049 shares. This raised procedural questions about whether LSI could introduce new arguments on appeal and whether it could rely on additional evidence (the investors’ affidavits) to support its revised position.
How Did the Court Analyse the Issues?
On the misrepresentation appeal (CA 57), the Court of Appeal approached the matter as a question of whether the trial judge’s conclusions were supported by objective evidence. The court found the trial judge’s evaluation persuasive and comprehensive. It rejected Goh’s “literalist” argument that because Peter Lim’s name was not repeated in later correspondence, it must not have been mentioned at the 24 October 2014 Meeting. The court emphasised that the absence of later repetition did not logically negate the possibility that the name was uttered at the earlier meeting.
More importantly, the Court of Appeal relied on corroborative evidence. Shortly after the 24 October 2014 Meeting, Gong informed Lin on WeChat that Peter Lim was the prospective buyer. The court reasoned that Gong could not have known Peter Lim’s name from Goh if Goh had not mentioned it at the meeting. The court also noted that Goh had admitted in his Further and Better Particulars dated 29 April 2016 that when he met Gong at the 24 October 2014 Meeting, he had informed her that Nelson Loh (a director of AMP) was negotiating a trade sale of AMP to Thomson Medical and/or Peter Lim. The Court of Appeal considered it unlikely that Goh, represented by counsel throughout, would have made mistakes in such pleaded particulars.
Even if Goh’s challenge about the identity of the prospective buyer were accepted, the court held that liability for fraudulent misrepresentation could still be established because the representation that a trade sale was imminent was itself sufficient. Fraudulent misrepresentation does not require that every detail be consistent across all subsequent documents; what matters is whether the representation made at the relevant time was false and fraudulent, and whether it induced the representee to enter the contract.
On inducement, the Court of Appeal reaffirmed the actionable nature of representations that play a real and substantial part in inducing the contract. It cited Panatron Pte Ltd v Lee Cheow Lee [2001] 2 SLR(R) 435 at [23] for the proposition that a representation is actionable so long as it played such a part. Applying that principle, the court agreed with the trial judge that the Trade Sale and IPO Representations played a real and substantial part in inducing Gong and Lin to procure LSI to enter into the SPA. The court accepted that the parties wanted to make a quick and handsome profit from a liquidity event, and the representations were directly aligned with that commercial objective.
On remedies and procedural fairness (CA 56 and SUM 100), the Court of Appeal addressed LSI’s attempt to reconfigure its case. LSI had originally argued, in substance, that it was entitled to rescind and recover damages as a trustee-like representative vis-à-vis the Chinese Investors, thereby seeking recovery for all 32,049 shares. However, during oral submissions, LSI shifted direction and advanced a “New Argument” that it was entitled to rescission in its personal capacity because it remained in possession of all the shares and could therefore furnish restitutio in integrum.
The Court of Appeal held that the “Trustee Argument” would have failed in any event. It was procedurally defective because LSI did not plead that it was suing in a representative capacity, contrary to the requirements under O 6 r 2(1)(c) of the Rules of Court (Cap 322, R 5, 2014 Rev Ed) (“ROC”). It also failed because LSI did not apply for leave to introduce a completely new argument on appeal, contrary to O 57 r 9A(4)(b) of the ROC. The court further reasoned that there was no good reason to entertain a trustee-based remedial claim that should have been clearly articulated from the outset in Suit 1311.
As for the “New Argument”, the court treated it as an impermissible attempt to change the remedial basis late in the appellate process. The court’s approach reflects a core principle of civil procedure: parties must plead their case properly at first instance so that the opposing party can respond and the court can determine the issues on the record. Allowing a late shift in the legal theory would undermine procedural fairness and the efficient administration of justice.
LSI also filed SUM 100 seeking leave to adduce the investors’ affidavits. The affidavits purported to show that the Chinese Investors had authorised LSI to commence Suit 1311 on their behalf, were willing to transfer the AMP shares back to Goh, and had not dealt with their beneficial interests. The Court of Appeal noted that SUM 100 was relevant only to the Trustee Argument. Given LSI’s radical change in direction during oral submissions, it was not surprising that LSI did not focus on SUM 100. In any event, the court’s refusal to accept the new remedial framework meant that the proposed additional evidence could not cure the fundamental pleading and procedural defects.
What Was the Outcome?
The Court of Appeal dismissed Civil Appeals Nos 55, 56 and 57 of 2019 and dismissed Civil Appeal Summons No 100 of 2019. In practical terms, this meant that the trial judge’s findings on fraudulent misrepresentation and inducement were upheld, and LSI did not obtain the expanded remedial relief it sought on appeal.
LSI therefore remained limited to the damages position awarded at first instance (as described in the oral judgment extract), and it could not rely on its revised arguments—whether framed as trustee-like rescission or personal-capacity rescission—to recover damages for all 32,049 shares. The court also did not permit LSI to adduce the investors’ affidavits through SUM 100.
Why Does This Case Matter?
Liberty Sky Investments Limited v Dr Goh Seng Heng is significant for two main reasons. First, it illustrates the evidential approach Singapore appellate courts take when reviewing findings of fraudulent misrepresentation. The Court of Appeal was willing to uphold the trial judge’s conclusions based on objective documentary and contemporaneous communications, and it rejected attempts to undermine those findings through overly literal arguments about what was or was not repeated in later correspondence.
Second, the case is a strong reminder that rescission and related equitable remedies are tightly controlled by both substantive requirements and procedural discipline. LSI’s attempt to reframe its remedial entitlement on appeal—by switching from a representative/trustee theory to a personal-capacity theory—was rejected because it was not properly pleaded and because leave to introduce new arguments was not obtained. For practitioners, the decision highlights that appellate advocacy cannot be used to cure foundational pleading omissions, especially where the new theory would require a different factual and legal inquiry.
Finally, the decision reinforces the causation standard for misrepresentation in contract formation: a representation is actionable if it played a real and substantial part in inducing the contract. The court’s analysis shows that where the commercial purpose of the transaction is closely tied to the alleged representations (here, a liquidity event to generate profit), inducement is likely to be inferred unless the evidence shows a genuine alternative basis for contracting.
Legislation Referenced
- Evidence Act
- Rules of Court (Cap 322, R 5, 2014 Rev Ed): O 6 r 2(1)(c); O 57 r 9A(4)(b)
Cases Cited
- Panatron Pte Ltd v Lee Cheow Lee [2001] 2 SLR(R) 435
- [2020] SGCA 7 (reported decision in this matter)
Source Documents
This article analyses [2020] SGCA 7 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.